onc Videos

Videos

Erika Martinelli, MD, PhD, Università degli Studi della Campania “L. Vanvitelli”

Videos

Upcoming Advancements in the Treatment of BRAF-Mutant, Metastatic Colorectal Cancer

08/23/2023

At the 2023 World Congress on Gastrointestinal Cancers, Erika Martinelli, MD, PhD, highlighted key upcoming advancements for the treatment of BRAF-mutant metastatic colorectal cancer.

At the 2023 World Congress on...

08/23/2023

Oncology

Alberto Sobrero, MD, Ospedale San Martino

Videos

Groundbreaking Advancements in Colorectal Cancer From the Past 25 Years

08/23/2023

Alberto F. Sobrero , MD;

At the 2023 World Congress on Gastrointestinal Cancers, Alberto Sobrero, MD, highlighted key advancements in colorectal cancer from the past 25 years.

At the 2023 World Congress on...

08/23/2023

Oncology

Videos

Bemarituzumab Plus FOLFOX Superior to FOLFOX Alone Among Patients With FGFR2b-Positive Metastatic Gastric Cancer

08/22/2023

Zev Wainberg , MD;

At the 2023 World Congress on Gastrointestinal Cancers, Zev Wainberg, MD, presented results from the final analysis of the phase 2 FIGHT trial.

At the 2023 World Congress on...

08/22/2023

Oncology

Patrick Tan, MD, PhD, Genome Institute of Singapore

Videos

New Strategies for Molecular Classification in Gastric Cancer

08/22/2023

Patrick Tan , MD, PhD;

At the 2023 World Congress on Gastrointestinal Cancers, Patrick Tan, MD, PhD, presented a keynote lecture on new strategies to achieve molecular classification in gastric cancer that can potentially inform the future treatment landscape.

At the 2023 World Congress on...

08/22/2023

Oncology

Monica Niger, MD, National Cancer Institute - MIlan

Videos

Clinical Relevance of BRAF Alterations in Biliary Tract Cancers

08/22/2023

Monica Niger , MD;

At the 2023 World Congress on Gastrointestinal Cancers, Monica Niger, MD, discusses the clinical relevance and actionability of BRAF alterations among patients with advanced biliary tract cancers.

At the 2023 World Congress on...

08/22/2023

Oncology

Videos

Incorporating IDH and Menin Inhibitors as Therapies for Subsets of Patients With AML

08/22/2023

Amir Fathi , MD;

At the 2023 Great Debates & Updates in Hematologic Malignancies Meeting, Amir Fathi, MD, shares insights on the emergence of IDH and menin inhibitors as therapies to target certain subsets of patients with acute myeloid leukemia.

At the 2023 Great Debates &...

08/22/2023

Oncology

Videos

Evolving Frontline Therapies for Patients With Newly Diagnosed Multiple Myeloma

08/22/2023

Peter M. Voorhees , MD;

Peter Voorhees, MD, discusses the latest updates in frontline therapeutic options for patients with newly diagnosed MM, a topic which he presented on at the 2023 Great Debates & Updates in Hematologic Malignancies meeting.

Peter Voorhees, MD, discusses...

08/22/2023

Oncology

Videos

Outcomes of Patients Treated With Abatacept for the Prevention of GVHD

08/22/2023

Benjamin Watkins , MD;

Benjamin Watkins, MD, provides insights into the latest research regarding patients treated with immunomodulator abatacept for the prevention of graft-versus-host disease.

Benjamin Watkins, MD, provides...

08/22/2023

Oncology

Videos

Evaluating Strategies and Approaches to Prevent Graft-Versus-Host Disease

08/22/2023

Benjamin Watkins , MD;

Benjamin Watkins, MD, discusses optimal options and strategies to employ for the prevention of the development of graft-versus-host disease following allogeneic stem cell transplant.

Benjamin Watkins, MD, discusses...

08/22/2023

Oncology

Alfonso De Stefano, MD, PhD, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione Giovanni Pascale

Videos

Intermittent vs Continuous Panitumumab Plus FOLFIRI for First-Line Treatment of Patients With RAS/BRAF Wild-Type Colorectal Cancer

08/21/2023

Alfonso De Stefano , MD, PhD;

At the 2023 World Congress on Gastrointestinal Cancers, Alfonso De Stefano, MD, PhD presented results of the IMPROVE study on intermittent or continuous panitumumab plus FOLFIRI for the first-line treatment of patients with RAS/BRAF wild-type...

At the 2023 World Congress on...

08/21/2023

Oncology

Recent News

News

FDA Grants Approval to Revumenib for Patients With R/R Acute Leukemia With KMT2A Translocation

11/17/2024

On November 15, 2024, the FDA approved menin inhibitor revumenib for adult and pediatric patients 1 year and older with relapsed/refractory acute leukemia with KMT2A translocation.

On November 15, 2024, the FDA...

11/17/2024

Oncology

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology